Bone News and Research

RSS

Genta reports net loss of $11.7M for fourth-quarter 2009

Genta Incorporated today reported results for the quarter and year ended December 31, 2009. The Company also provided an overview of recent corporate highlights and anticipated milestones.

29 Mar 2010

IOF invites for Asia-Pacific Osteoporosis Meeting in Singapore

The International Osteoporosis Foundation (IOF) invites you to attend the first of a new series of meetings - the IOF Regionals: Asia-Pacific Osteoporosis Meeting, to be held in Singapore from December 10-13, 2010.

29 Mar 2010

Lymph node radiotherapy well-tolerated after mastectomy or breast conserving surgery

In patients with early breast cancer, giving radiotherapy to the lymph nodes located behind the breast bone and above the collar bone is well-tolerated, after mastectomy or breast conserving surgery, a radiation oncologist will tell delegates at the seventh European Breast Cancer Conference (EBCC7) today (Saturday 27 March).

27 Mar 2010

Radio ad supports legislation to end cash for egg donation

Today, Family Research Council Action and the Oklahoma Family Policy Council released a radio advertisement supporting State Representative Rebecca Hamilton's Oklahoma House Bill 3077, currently being reviewed by the Oklahoma State Senate. H.B. 3077 would put an end to the financial lure that draws young women into donating their eggs to fertility clinics, a dangerous procedure that can cause life-threatening complications including kidney failure and blood clots.

27 Mar 2010

Fundamental step in immune system development discovered

Researchers at National Jewish Health have discovered a fundamental step in the development of the immune system, one that allows B cells to mature and fight disease by producing effective antibodies. Immunologist Roberta Pelanda, PhD, and her colleagues have demonstrated that immature B cells in the bone marrow must receive a positive signal before they can migrate to the spleen where they mature and are activated. In the March 15, 2010 issue of The Journal of Experimental Medicine, the researchers also reported that a protein known as Erk helps deliver that positive signal.

26 Mar 2010

NCMHD announces $3.8M grant for research on minority recruitment in cancer clinical trials

The University of Minnesota Medical School today announced the details of a $3.8 million grant by the National Institutes of Health's National Center on Minority Health and Health Disparities for research focused on minority recruitment and retention in cancer clinical trials.

26 Mar 2010

New devices pave way for applications in cardiology and neurology

A team of cardiologists, materials scientists, and bioengineers have created and tested a new type of implantable device for measuring the heart's electrical output that they say is a vast improvement over current devices. The new device represents the first use of flexible silicon technology for a medical application.

26 Mar 2010

Two separate articles describing preclinical data of ACE-041 published

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, announced the publication of two separate peer-reviewed articles describing preclinical data demonstrating that treatment with ACE-041, an inhibitor of signaling through the activin receptor-like kinase 1 receptor, slows tumor growth and progression by inhibiting angiogenesis.

26 Mar 2010

$UCSF study: Unusual femur fractures low in patients with osteoporosis$

UCSF study: Unusual femur fractures low in patients with osteoporosis

The occurrence of an unusual type of fracture of the femur, or the thigh bone, is very low in patients with osteoporosis, including those treated with the drug family known as bisphosphonates, according to a new study led by a team of UCSF epidemiologists.

26 Mar 2010

New gateway may be lifesaver for patients with AML: Study

Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The findings from the Universit- de Montr-al, Maisonneuve-Rosemont Hospital and Universit- Laval may change the way doctors treat cancer patients.

26 Mar 2010

Aastrom Biosciences' RESTORE-CLI trial: Final patient treated

Aastrom Biosciences, Inc., a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported that the final patient has been treated in the company's ongoing multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. This patient received intramuscular injections of either Aastrom's tissue repair cells (TRCs) or electrolyte solution (placebo) for the treatment of critical limb ischemia (CLI), the end-stage of peripheral arterial disease.

26 Mar 2010

FDA approves Riverain Medical's Softview Enhanced Chest Imaging technology

Riverain Medical, a leading image enhancement and computer-aided detection company dedicated to providing physicians with tools to assist in image interpretation, announced today that the U.S. Food and Drug Administration (FDA) has cleared the SoftView Enhanced Chest Imaging technology.

25 Mar 2010

Drilling technology used to reopen arteries

Then Wilks was referred to Dr. Fred Leya, an interventional cardiologist at Loyola University Health System. Leya used a device similar to a dental drill to reopen three arteries that had turned as hard as bone.

25 Mar 2010

$Osteoporosis drugs falsely implicated in rare thigh bone fractures, say new reports$

Osteoporosis drugs falsely implicated in rare thigh bone fractures, say new reports

Osteoporosis is a disease of the bones usually affecting elderly women and causes the bones to become brittle and easily breakable. Since last two years some alarming reports of women on drugs for therapy of this disease have come to notice. These reports show that these drugs intended for therapy may result in rare and serious fractures of their thigh bones where the bones break clean or may splinter. Often these fractures were not associated with any fall or impact. Moreover some of the sufferers are middle aged women in their 50’s who do not have full blown osteoporosis, a condition known as pre-osteoporosis or osteopenia.

25 Mar 2010

Axis Surgical's EC-MOR facilitated real-time visualization of anterior spine column during surgery

Axis Surgical Technologies, Inc., reports the first evaluation of the C-MOR™ Visualization Device in a spine procedure. The C-MOR™ is a self-contained portable direct-imaging tool that functions much like a standard arthroscopic tower, yet at a fraction of both the size and cost. The handheld lightweight device offers practitioners the convenience of intraoperative visualization and complete operability in one hand. The C-MOR™ comprises a distinctive and cost-effective imaging device offering benefits to medical practitioners in a variety of applications, including lengthy surgeries requiring constant re-evaluation of the operating field over the course of the surgery.

25 Mar 2010

Bone stem cells could become a part of new, innovative hip replacement treatment

Bone stem cells could in future be used instead of bone from donors as part of an innovative new hip replacement treatment, according to scientists at the University of Southampton.

24 Mar 2010

Bergen research group adopts nanotechnology for cancer research

Professor James Lorens and his team at the University of Bergen's Department of Biomedicine are using nanotechnology to study how to make cells form new blood vessels, both within the patient's body and in the laboratory. In the next phase the team will use this knowledge to investigate the molecular mechanisms that govern the progression of cancer.

24 Mar 2010

Gentium presents abstract on Defibrotide at EBMT Annual Meeting

Gentium S.p.A.today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicenter study," was presented on Sunday, March 21, 2010, at the opening session of the European Blood and Marrow Transplantation 36th Annual Meeting in Vienna. The abstract received the esteemed Van Bekkum Award for the best abstract submitted to the physician's program. Dr. Selim Corbacioglu, Professor of Pediatrics, University of Regensburg (Germany) and Principal Investigator of the Pediatric Prevention trial, accepted the award and presented the final results of the study.

24 Mar 2010

Bioheart to open five centers to provide cell therapy procedures for congestive heart failure patients

Bioheart, Inc., announced today plans for establishing five Centers of Excellence in Latin America to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease beginning next month, April 2010. Bioheart entered into its first agreement with a leading treatment facilitator, Regenerative Medicine Institute of Tijuana, Mexico. Therapies for CHF and PAD patients will be made available at the Hospital Angeles Tijuana, a fully equipped state-of–the-art private specialties hospital. This will be the first of five Centers of Excellence with four additional Centers to be announced in the coming months.

24 Mar 2010

Study reveals facial bone changes add to aging appearance

Facelifts and other wrinkle-reducing procedures have long been sought by people wanting to ward off the signs of aging, but new research suggests that it takes more than tightening loose skin to restore a youthful look.

24 Mar 2010